Abiant, Inc. 480 West Center Street, Suite 202, Grayslake, Illinois 60030
New and Events...
Abiant Presents at ICAD and is featured in ICAD News Briefing
Deerfield, ILLINOIS - - July 14, 2009 - - Abiant was selected to be featured in a news briefing at the 2009 International Conference on Alzheimer's Disease (ICAD) on July 14, 2009. Later that afternoon, Abiant gave a more in-depth scientific presentation titled "Regional Cerebral Glucose Metabolism at Baseline Predicts Symptom Onset in Normal ADNI Subjects and Correlates to Disease Progression". These presentations focused on the results of analyses performed using the neuroimaging scans in 250 patients in the ADNI database.
ICAD, sponsored by the Alzheimer's Association (www.alz.org), is one of the world's largest and premier conferences on the care, diagnosis, and treatment of Alzheimer's Disease. The conference will take place from July 11 - 16 in Vienna, Austria.
ADNI is a $60 million, 5-year public-private partnership to test whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer’s disease (AD). Additional information can be found at the ADNI website.
Abiant, Inc. uses proprietary image analysis methods and software to provide sensitive biomarkers of drug effects and disease progression. The imaging information, which includes biochemical, functional, and structural measurements, is intended to accelerate or reduce risk of decision making in both drug development and disease treatment.
This press release may contain "forward-looking" statements identified by words such as “will,” "achieve," and "enable." There are a number of important factors that could cause Abiant's results to differ materially from those indicated by these forward-looking statements.